Clinical trial / 2001
Glucosamine sulphate prevented progressive joint-space narrowing and improved symptoms over 3 years in knee osteoarthritis patients.
In a 3-year randomized trial, 212 patients with knee osteoarthritis received either 1500 mg oral glucosamine sulphate or placebo once daily. Patients on placebo experienced progressive joint-space narrowing with a mean joint-space loss of -0.31 mm (95% CI -0.48 to -0.13), whereas patients taking glucosamine sulphate had no significant loss (-0.06 mm, 95% CI -0.22 to 0.09). WOMAC scores showed symptoms worsened slightly on placebo but improved with glucosamine sulphate, with no differences in safety or reasons for early withdrawal between groups.
- Study type
- Randomised, double-blind, placebo-controlled trial
- Who was studied
- 212 patients with knee osteoarthritis
- What was measured
- Mean and minimum joint-space width, WOMAC osteoarthritis index scores, safety
THE PAPER
Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial.
Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, Giacovelli G, Henrotin Y, Dacre JE, Gossett C. Lancet, 2001.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.